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Abstract 
Background: Polymorphisms of vitamin D receptor (VDR) gene have been studied as genetic markers of type 1 
diabetes mellitus (T1DM) and some studies have reported associations with autoimmune thyroid disease. The aim of 
this study was to evaluate the relationship between VDR FokI polymorphism (rs10735810), thyroid autoimmunity and 
thyroid dysfunction (TD) in Brazilian T1DM.
Methods: One-hundred-eighty T1DM patients were evaluated for age, duration of diabetes (DDM), positivity to TPO 
Antibody (TPOA), GAD Antibody (GADA), IA2 Antibody (IA2A) and fasting serum C-peptide (FCP) according to diagno-
sis of TD. PCR–RFLP analyses were carried out for VDR polymorphism FokI.
Results: TPOA positivity (80.0 vs. 25.0 %, p < 0.001) and GADA positivity (56.0 vs. 30.3 %, p = 0.01) were higher in 
T1DM patients with TD with the same age and DDM than the group without TD, with no difference of FCP and IA2A 
positivity. We observed higher prevalence of VDR FokI in T1DM with TD (ff and Ff 73.9 % with TD vs. 52.7 % without TD, 
p = 0.05). Positivity to TPOA and presence of FokI polymorphism were significantly associated with the concurrence of 
TD in T1DM patients (OR 18.1; CI 3.7–87.0; p < 0.001).
Conclusions: The VDR FokI polymorphism (rs10735810) was associated to persistence of GADA, TPOA positivity and 
TD in Brazilian T1DM. Positivity to TPOA and VDR polymorphism FokI were strongly associated with concurrence of 
T1D and TD. These data collaborate to understanding the joint susceptibility genes for TD in T1DM.
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Background
Type 1 diabetes mellitus (T1DM) often is associated 
to other autoimmune diseases, and the most frequent 
observed is autoimmune thyroid disease (AITD) [1–4].
Fifteen to 30  % of T1DM patients have autoimmune 
thyroid disease, as well as, 8 % of their first-degree rela-
tives, showing an increased risk for autoimmune disease. 
Thyroid autoimmunity is increased in females and with 
longer duration of diabetes [4].
A possible explanation for the coexistence of thyroid 
and pancreatic autoimmunity can be found in share 
genetic background [5–9] and each disease is thought to 
be influenced by multiple susceptibility genes, as well as 
environmental factors [10].
Immune-modulating genes like HLA class II region 
gene, CTLA-4, CD40, PTNP22 and thyroid-specific 
genes [thyroglobulin and thyroid-stimulating hormone 
receptor (TSHR)] are involved in development of AITD 
[10, 11]. Of these, studies showed that HLA class II genes, 
CTLA-4, PTNP22 and FOXP3 contribute to susceptibil-
ity to both, T1DM and AITD [7, 8, 11–13]. All of them 
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T cell activation. This observation demonstrated that the 
majority of the genes associated with elevated disease 
risk relate to the function of the immune system [13, 14].
Vitamin D has been recognized for its effects on the 
immune system [15] and polymorphisms of vitamin D 
receptor gene (VDR) have been studied as genetic mark-
ers of T1DM [16] and of AITD [16–22].
In healthy populations, the BsmI and TaqI bb genotype 
frequency was 2  % among Asians, 5  % among African 
Americans and 17  % among Caucasians while the ApaI 
AA genotype was 9, 44 and 28 % respectively. [23].
The VDR FokI polymorphism in exon 2 leads to an 
alternative transcription initiation site resulting in a VDR 
protein with addition of three amino acids [24]. A func-
tional role of this VDR polymorphism on the immune 
response has been previously described. It was observed 
in  vitro that lymphocytes without VDR FokI polymor-
phism proliferated more strongly, with more active 
immune response and, monocytes and dendritic cells 
without polymorphism produced higher levels of IL-12 
p70 protein after stimulation [25].
Despite the well-known association among T1DM, thy-
roid auto antibodies and clinical AITD, there have been 
relatively few reports on the shared genetic susceptibility 
for these three events [5, 6, 13–22].
Our group had previously studied VDR gene poly-
morphism FokI and T1DM, and we have not observed 
relationship with beta cell autoimmunity. Nevertheless, 
T1DM individuals with this polymorphism tended to 
have lower residual pancreatic beta cell function when 
they were compared with their pairs with the same dura-
tion of disease but without the polymorphism studied 
[26].
The aim of the present study was to evaluate the rela-
tionship between presence of VDR gene polymorphism 
FokI (rs10735810), thyroid dysfunction (TD) and thyroid 
autoimmunity in a group of Brazilian T1DM.
Methods
Study population
We evaluated 180 patients with T1DM according to ADA 
criteria [27] attending the Diabetes Center of São Paulo 
Federal University, SP, Brazil. The study was approved 
by the Ethics Committee of São Paulo Federal Univer-
sity, Brazil (number 0814/03) and informed consent was 
obtained from the subjects’ parents.
Clinical evaluation
Patients with T1DM from UNIFESP Diabetes Center 
were evaluated for age, sex, body mass index (BMI, kg/
m2), age at diagnosis and time from diabetes mellitus 
diagnosis (TDD) and diagnosis of thyroid dysfunction. In 
those patients with TD we also evaluated age at diagnosis 
and time between development of diabetes and TD. The 
inclusion criteria used were: patients diagnosed with type 
1 diabetes, according to ADA and with the presence of 
thyroid antibody or TSH and/or free T4 alteration.
Exclusion criteria were: patients who presented hypo-
thyroidism due to other causes: iodine deficiency, post 
thyroid ablation.
Hypothyroidism and hyperthyroidism were clini-
cally diagnosed and confirmed according to TSH levels. 
Thyroid dysfunction was diagnosed in the presence of 
a serum TSH alteration (normal 0.5–5.0  mUI/mL) with 
or without symptoms. Hypothyroidism was confirmed 
if TSH levels >5.0 mUI/mL and hyperthyroidism if TSH 
levels were bellow 0.5 mUI/mL. All patients with hypo-
thyroidism were taking levothyroxine. Two patients 
with hyperthyroidism were treated with metimazol with 
remission of the disease after 1.5 and 1 year, and another 
one was still using 30 mg daily of this drug.
We considered presence of thyroid autoimmunity posi-
tivity for thyroid peroxidase antibodies (TPOA).
Biochemical analysis
TSH was measured using an immunofluorometric assay 
developed in the Laboratory of Molecular Endocrinol-
ogy of the Federal University of São Paulo, Brazil (nor-
mal range: 0.5–5.0  mUI/mL). TPOA were measured by 
an immunofluorometric assay (autoDelfia, Turku, Fin-
land) and we considered the reference value <52  U/mL 
for the population studied. Glutamic acid decarboxylase 
65 (GADA) and Insulinoma antigen-2 (IA2A) antibodies 
were measured by a radioimmunoassay (RSR Ltd, Car-
diff, UK) and according to previous study of our group 
we considered the reference value <1.72 and 0.97 U/mL 
respectively [28]. Fasting serum C-peptide (FCP) was 
measured using an immunofluorometric assay (autoDel-
fia, Turku, Finland) with detection limit of 0.015 ng/mL. 
The intra-assay variation was 4.2  % (0.52–6.11  ng/mL) 
and inter-assay variation of 1.1  % (0.52  ng/mL), 3.4  % 
(6.11 ng/mL). Glycated hemoglobin (HbA1c) was meas-
ured in whole blood by HPLC (TOSOH, Japan; normal 
range 3.5–6.0 %).
Genomic DNA extraction and genotyping
Genomic DNA was extracted from peripheral leukocytes 
using a commercial kit (PureGene Genome DNA Isolation 
Kit, Gentra Systems, Minneapolis, USA) and amplified by 
polymerase chain reaction (PCR). The forward primer 
for FokI polymorphism (rs10735810, Genbank acces-
sion no AC004466) was 5′ AGCTGGCCCTGGCACT 
GACTCTGCTCT3′ and the reverse primer was 5′ ATGGA 
AACACCTTGCTTCTTCTCCCTC3′. The PCR condi-
tions for the FokI polymorphism were 94  °C for 5  min 
and 35 cycles using the following profile: 94 °C for 30 s, 
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60 °C for 30 s and 72 °C for 1 min and a final extension at 
72 °C for 10 min. It was followed by restriction fragment 
length polymorphism according to previous reports for 
the VDR polymorphism FokI [25]. Genotypes were deter-
mined by 1.8 % agarose gel electrophoresis and defined as 
lower case with the presence of restriction site and capi-
tal letters for its absence.
Statistical analysis
Values are expressed as mean  ±  SD. Statistical analy-
ses were performed with a SPSS for Windows version 
13.0 (SPSS Inc. Chicago,Il, USA). We used Student’s t 
test, Mann–Whitney test (when variables not normally 
distributed) and χ2 tests to compare the demographics, 
clinical and laboratory characteristics of T1DM group 
according to presence or absence of TD. Logistic regres-
sion was performed in T1DM patients to assess the role 
of VDR FokI polymorphism in the concurrence of T1DM 
and TD by including the genotypes of the VDR polymor-
phism. p values  <0.05 were considered statistically sig-
nificant. Hardy–Weinberg equilibrium was calculated to 
evaluate the gene and genotype frequencies expected and 
observed.
Results
Screening for thyroid antibodies and function was per-
formed in 180 T1DM with different time of clinical dia-
betes diagnosis.
TPOA was positive in 32.6  % (58/178) patients and 
TD was observed in 14 % (25/178). Twenty-two patients 
developed primary hypothyroidism and three hyperthy-
roidism after mean time of T1DM diagnosis of 3 years.
TPOA positivity (80.0 vs. 25.0 %, p < 0.001) were higher 
in T1DM patients with TD comparing to those patients 
that have not developed this dysfunction. Furthermore, 
the female gender (72.0 vs. 48.4 %, p = 0.02) and GADA 
positivity (56.0 vs. 30.3  %, p  =  0.01) were also higher 
in T1DM patients with TD. There were no difference 
between groups related to age, age at diagnosis of diabe-
tes, TDD, residual beta-cell function (FCP) and glycemic 
control (HbA1c).
Demographic, clinical, laboratory characteristics and 
prevalence of FokI polymorphism are shown according to 
presence or absence of TD (Table 1).
VDR polymorphism FokI genotypes frequencies were 
in equilibrium of Hardy–Weinberg.
We observed higher frequency of homozygosis and 
heterozygosis for the VDR FokI polymorphism in T1DM 
patients with TD comparing to those without (ff plus 
Ff genotypes 73.9  % with TD vs. 52.7  % without TD, 
p = 0.05; Fig. 1).
An analysis with interactive terms in a logistic regres-
sion with FokI polymorphism and positivity to TPOA 
and to GADA was performed. T1DM patients with posi-
tivity to TPOA and FokI polymorphism showed 18-fold 
increased risk of developing TD (OR 18.1, p  <  0.001; 
Table  2), whereas for the concurrence of GADA titers 
and the presence of FokI polymorphism the risk was of 8 
times higher (OD 8.8, p = 0.009).
Discussion
In a group of young T1DM patients and we found higher 
frequency of VDR FokI polymorphism in individuals 
with thyroid auto antibodies without relation to age and 
duration of diabetes. The titers of thyroid autoantibodies 
Table 1 Demographic, clinical, laboratory characteris-
tics and  prevalence of  VDR FokI polymorphism of  T1DM 
patients according to presence or absence of thyroid dys-
function (TD)
Data are expressed as mean ± SD unless otherwise indicated
TDDM time of duration of diabetes, FCP fasting serum C-peptide
With TD Without TD p
n (%) 25 (13.9) 155 (86.1)
Gender (female %) 72.0 48.4 0.02
Age (years) 16.8 ± 7.1 17.1 ± 5.0 0.28
Age at diagnosis of diabetes (years) 10.0 ± 4.0 10.2 ± 5.1 0.80
TDDM (years) 6.9 ± 6.3 6.9 ± 5.2 0.72
Age at diagnosis of TD (years) 13.8 ± 6.5 –
BMI (kg/m2) 21.3 ± 3.2 22.0 ± 3.6 0.18
TSH (mUI/mL) 19.1 ± 59.0 2.2 ± 1.4 0.00
TPO Ab positive (%) 80.0 25.0 <0.001
GAD Ab positive (%) 56.0 30.3 0.01
IA2 Ab positive (%) 36.0 43.1 0.50
FCP (ng/mL) 0.18 ± 0.29 0.19 ± 0.42 0.77
A1c (%) 9.3 ± 1.6 9.2 ± 1.8 0.75
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Fig. 1 Frequency of positivity to GADA and to TPOA and prevalence 
of VDR FokI polymorphism according to thyroid dysfunction
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and GADA were higher in T1DM with TD. Positivity to 
TPOA and presence of FokI polymorphism were signifi-
cantly associated with the concurrence of TD in T1DM 
patients. This is the first study that studied the associa-
tion between those concomitant endocrine autoimmune 
diseases and VDR polymorphism in Brazilian T1DM 
patients.
T1DM and TD are autoimmune disease with common 
background. Both have the production of autoantibod-
ies directed at the target organs (thyroid and pancreatic 
islets) and T cells-infiltration, resulting in their dysfunc-
tion and destruction. As autoimmunity progresses from 
initial activation to a chronic state, there is often an 
increase in the number of autoantigens targeted by 
T-cells and autoantibodies. T-cells activate additional 
autoreactive B-cells, and B-cells present additional 
epitopes from different proteins, until there is autoreac-
tivity to diverse autoantigens [29]. Some authors consider 
the co-occurrence of T1DM and AITD in the same indi-
vidual as one of the variants of autoimmune polyglandu-
lar syndrome type 3 (APS3s) [30].
Recent studies have evaluated shared genetic suscepti-
bility to T1DM and Thyroid Autoimmune Disease [5–8, 
12]. Nevertheless, studies with VDR polymorphisms did 
not evaluate individuals with these concomitant diseases 
[17–19]. Regarding these polymorphisms and thyroid 
disease distinct results have been reported. Japanese 
studies reported an association between VDR FokI poly-
morphism, Hashimoto’s Thyroiditis and Graves’ disease 
[18, 19]. In German and Polish individuals this polymor-
phism was associated with Graves’ disease [19], but the 
same was not observed in patients from United Kingdom 
[20] and Tunisia [21]. In the Croatian population was 
described an association between VDR polymorphisms 
haplotypes and Hashimoto’s thyroiditis risk [22]. In 
T1DM, BsmI polymorphism has been also linked to sus-
ceptibility to present the disease in Taiwanese, Japanese, 
Croatians and Southern Indians [31–33].
Our finding of higher frequency of VDR FokI polymor-
phism in individuals with T1DM, thyroid auto antibodies 
and TD suggest that this polymorphism may be another 
loci that affect the development of both clinical diseases.
The susceptibility genes for T1DM and AITD identified 
to date, HLA class II, CTLA-4, PTNP22 and FOXP3 are 
involved in the immunological synapse and T cell acti-
vation [8, 34]. Van Etten et  al. [25] had studied in  vitro 
the role of FokI polymorphism in autoimmunity and 
described that monocytes and dendritic cells without pol-
ymorphism produced higher levels of IL-12 p70 protein 
after stimulation. In BioBreeding rat, an animal model for 
AITD and diabetes, was observed an imbalance between 
cytokines secreted by Th1 and Th2 lymphocytes. IL-12 
mRNA expression was increased in pancreatic islets and 
also in thyroid gland of those diabetic animals [35]. This 
is the major cytokine that induces a T helper 1 response, 
resulting in β cell destruction in T1DM [36]. Our study 
was not aim to evaluate the immune response but fur-
ther studies are necessary to determine the relationship 
between cytokines, VDR polymorphism, thyroid autoim-
munity and TD in T1DM patients.
In this study we observed a higher prevalence of 
VDR FokI polymorphism in a group of T1DM Brazilian 
patients with a mean of 7 years of diabetes and 3 years of 
TD, which presented with persistence of GADA positivity 
and higher prevalence of TPOA positivity. Furthermore, 
positivity to TPOA and presence of VDR polymorphism 
FokI were strongly associated with the presence of TD in 
T1DM patients. It was previously reported a tendency 
of higher frequency of thyroid auto antibodies in T1DM 
patients with HLA DR3/DR4 [37]. Also, a strong corre-
lation between G allele of CTLA-4 gene polymorphism 
(rs 3087243) with TPOA was observed [38]. In Japan, two 
SNPs rs 2292399 in ERBB3 and rs 2903692 in CLEC16A 
were associated with T1DM complicated with thyroid 
auto antibodies [6]. Concerning VDR polymorphisms, 
previous studies did not evaluate the relationship with 
thyroid auto antibodies [17–22].
An association between positivity to GADA and TPOA 
had been described in T1DM patients from differ-
ent populations [3, 39–41]. Moreover, it was previously 
described an association between PTNP22 1858T geno-
type and GADA positivity in a group of T1DM patients 
with long disease duration, suggesting that this genetic 
variant may help define a subgroup of patients with 
Table 2 ORs adjusted by  logistic regression of  associated 
variables for  the association with  thyroid dysfunction 
in T1DM
TPOAb thyroid peroxidase antibody
T1DM B p value OR 95 % CI
Without TPOAb and without  
FokI polymorphism
1.0
Without TPOAb and with  
FokI polymorphism
0.346 0.711 1.4 (0.2–8.8)
With TPOAb and without  
FokI polymorphism
1.812 0.047 6.1 (1.0–36.6)
With TPOAb and with  
FokI polymorphism
2.893 <0.001 18.1 (3.7–87.0)
Without GADAb and without  
FokI polymorphism
1.0
Without GADAb and with  
FokI polymorphism
1.356 0.093 3.9 (0.8–18.9)
With GADAb and without  
FokI polymorphism
1.433 0.114 4.2 (0.71–24.7)
With GADAb and with  
FokI polymorphism
2.175 0.009 8.8 (1.71–45.2)
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persistence of GADA [42]. A single nucleotide polymor-
phism (rs 3087243) of CTLA4 was associated with AITD, 
but not with positivity of GADA [43]. In this study we 
observed that positivity to GADA and presence of FokI 
polymorphism were significantly associated with the 
concurrence of TD in T1DM patients with an average of 
7 years of disease.
Nevertheless, the VDR FokI polymorphism might be 
another susceptibility loci for thyroid autoimmunity and 
an additional genetic marker that in association with auto 
antibodies might help identifying T1DM patients with 
higher risk of TD.
We observed hypothyroidism in 12.2 % of T1DM with a 
mean of 7 years of duration of diabetes, similar to observed 
in a prospective study that described a cumulative inci-
dence of autoimmune thyroiditis of 14  % in pediatric 
T1DM patients at 10 years of diagnosis [44]. The diagnosis 
of T1DM preceded the development of TD in this group, 
as previously observed by our group [45]. In addition, 72 % 
of T1DM patients who developed TD were female and had 
also higher prevalence of thyroid autoimmunity, in accord-
ance with previous studies [1, 2, 38, 46, 47].
In conclusion, the present study demonstrated that the 
VDR FokI polymorphism (rs10735810) was associated 
to persistence and high titers of GADA, TPOA positiv-
ity and TD in Brazilian T1DM patients. The presence of 
VDR polymorphism FokI was strongly associated with 
concurrence of T1DM and TD in this sample population. 
These data collaborate to understanding the joint sus-
ceptibility genes for TD in T1DM and could potentially 
improve the predictive value for this disease combination 
development.
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